You are here

Merck

Homegrown rivals to Pfizer, Merck cash cow vaccines win nods in China

Fierce Pharma

Sun, 01/5/20 - 07:07 pm

Why Biotech Stock ArQule Soared 108% in December

Motley Fool

Sat, 01/4/20 - 07:27 pm

Corporate and regulatory developments over the Christmas period

EP Vantage

Thu, 01/2/20 - 11:39 pm

Ono Pharmaceutical

Xyphos Biosciences

FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer

BioSpace

Mon, 12/30/19 - 05:39 pm

pancreatic cancer

FDA clears Eisai’s insomnia drug Dayvigo

Pharmaforum

Mon, 12/30/19 - 11:01 am

FDA approves an Ebola vaccine, long in development, for the first time

Stat

Thu, 12/19/19 - 11:04 pm

Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK

Fierce Pharma

Wed, 12/18/19 - 10:50 am

AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer

Fierce Pharma

Tue, 12/17/19 - 09:19 pm

pancreatic cancer

advisory panels

After big M&A year, will pharma move away from massive deals in 2020?

Fierce Pharma

Mon, 12/16/19 - 10:29 pm

Bristol-Myers Squibb

Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide

Fierce Pharma

Mon, 12/16/19 - 10:42 am

BRCA-mutated pancreatic cancer

pancreatic cancer

SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short

Fierce Pharma

Thu, 12/12/19 - 11:12 am

immuno-oncology

triple-negative breast cancer

Deserted by Astellas and Merck, little Correvio still can't win over FDA panel concerned with its AFib drug's safety

Endpoints

Wed, 12/11/19 - 10:29 am

clinical trials

atrial fibrillation

Leukemia rivals try to stay ahead as Merck, Lilly chase

Biopharma Dive

Tue, 12/10/19 - 11:53 pm

Merck to acquire ArQule for $20 per share in cash or about $2.7 billion

Marketwatch

Mon, 12/9/19 - 10:06 am

KalVista's diabetic macular edema data falls short — will Merck walk away?

Endpoints

Mon, 12/9/19 - 09:58 am

diabetic macular edema

Following Merck approval, Gavi authorizes $178M to build Ebola vaccine stockpile

Fierce Pharma

Fri, 12/6/19 - 10:28 am

Turning Merck's COPD drug against resistant prostate cancer

Fierce Biotech

Wed, 12/4/19 - 11:22 pm

prostate cancer

Merck, insurers fight over $1.3B in damages from cyberattack: Bloomberg

Fierce Pharma

Wed, 12/4/19 - 10:18 am

Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors

Motley Fool

Wed, 12/4/19 - 09:57 am

Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

Fierce Pharma

Tue, 12/3/19 - 10:42 pm

nadofaragene firadenovec

Pages